TRUMY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 13.44% compared to Terumo's net margin of -6742.11%. Terumo's return on equity of 8.61% beat Healios KK's return on equity of -196.15%.

Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than Healios KK, analysts believe Terumo is more attractive than Healios KK.

Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.87%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Terumo quarterly revenues are $1.7B, which are larger than Healios KK quarterly revenues of $249.2K. Terumo's net income of $232.2M is higher than Healios KK's net income of -$16.8M. Notably, Terumo's price-to-earnings ratio is 34.30x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.88x versus 76.64x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 13.44% compared to Terumo's net margin of -24.41%. Terumo's return on equity of 8.61% beat PeptiDream's return on equity of 34.1%.

Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than PeptiDream, analysts believe Terumo is more attractive than PeptiDream.

Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.87%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Terumo quarterly revenues are $1.7B, which are larger than PeptiDream quarterly revenues of $27.8M. Terumo's net income of $232.2M is higher than PeptiDream's net income of -$6.8M. Notably, Terumo's price-to-earnings ratio is 34.30x while PeptiDream's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.88x versus 5.17x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 13.44% compared to Terumo's net margin of -11.44%. Terumo's return on equity of 8.61% beat Nxera Pharma's return on equity of -8.65%.

Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than Nxera Pharma, analysts believe Terumo is more attractive than Nxera Pharma.

Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.87%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Terumo quarterly revenues are $1.7B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Terumo's net income of $232.2M is higher than Nxera Pharma's net income of -$5M. Notably, Terumo's price-to-earnings ratio is 34.30x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.88x versus 3.51x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 13.44% compared to Terumo's net margin of -9.79%. Terumo's return on equity of 8.61% beat Takeda Pharmaceutical's return on equity of 1.49%.

Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.15 which suggests that it could grow by 13.72%. Given that Takeda Pharmaceutical has higher upside potential than Terumo, analysts believe Takeda Pharmaceutical is more attractive than Terumo.

Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.87%. Takeda Pharmaceutical offers a yield of 4.07% to investors and pays a quarterly dividend of $0.33 per share. Terumo pays 30.45% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Terumo quarterly revenues are $1.7B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Terumo's net income of $232.2M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Terumo's price-to-earnings ratio is 34.30x while Takeda Pharmaceutical's PE ratio is 69.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.88x versus 1.63x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.